首页> 外文会议>International Stereotactic Radiosurgery Society >Potent inhibitory EfectsofaNO-NSAIDCFlurbiprofenNitroxybutylester) on Bone Resorption In Vitro and In Vivo
【24h】

Potent inhibitory EfectsofaNO-NSAIDCFlurbiprofenNitroxybutylester) on Bone Resorption In Vitro and In Vivo

机译:有效的抑制性Efectsofano-nsaidcflurbrofennitroxybutyless在体外和体内骨吸收上

获取原文

摘要

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely employed in the treatment of musculoskeletal disorders but their use is limited by adverse effects on the gastrointestinal tract. A new class of NSAIDs, containing a nitric oxide (NO)-donor moiety (NO-NSAID) has been developed which retain the desired anti-inflammatory and analgaesic properties of NSAIDs but which do not cause gastrointestinal side effects, because the vasodilator effects of NO counteract the adverse effects of COX-1 inhibition on gastric mucosa [1,2]. Previous studies have shown that prostaglandins and nitric oxide play an important role in regulating bone cell function [3,4]. Since NO-NSATDs combine the properties of a NO donor with those of a COX inhibitor, we have investigated the effects of the NO-NSATD flurbiprofen nitroxybutylester (HCT1026) on bone resorption in vitro and in vivo.
机译:非甾体抗炎药(NSAID)广泛用于治疗肌肉骨骼疾病,但它们的使用受到对胃肠道的不利影响的限制。已经开发了一种新的NSAID,含有一氧化氮(NO)-DonOR部分(NO-NSAID),其保留了NSAID的所需抗炎和分枝性能,但不会导致胃肠副作用,因为血管扩张效应无抵消COX-1抑制对胃黏膜的不利影响[1,2]。以前的研究表明,前列腺素和一氧化氮在调节骨细胞功能方面发挥着重要作用[3,4]。由于No-NSATDS将NO助力剂与COX抑制剂的性质结合起来,因此我们研究了NO-NSATD Flbiprofen NITROXYBUTYLENTES(HCT1026)对体外和体内骨吸收的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号